LGC LIMITED

Their core work

LGC is a UK-based measurement and standards company specializing in reference materials, proficiency testing, and genomic services. Within H2020, they contribute expertise in pre-analytical standardization for diagnostics, advanced DNA sequencing technologies, and biomarker validation for clinical applications. Their work bridges the gap between laboratory measurement science and real-world clinical and genomic applications, ensuring that analytical methods are reproducible, standardized, and fit for regulatory use. They bring commercial-grade quality assurance and ISO-level rigor to research consortia.

What they specialise in

How they've shifted over time

LGC's early H2020 involvement (2017) included broad interdisciplinary research training via the WIRL programme, focused on cross-sectoral mobility and leadership development. By 2019, the focus shifted decisively toward technical genomics infrastructure and clinical biomarker applications — DNA sequencing, multi-omics, and dementia diagnostics. This evolution reflects a move from general capacity building toward deploying their core measurement science capabilities in high-impact health and genomics domains.

LGC is deepening its involvement in clinical genomics and multi-omics diagnostics, making them a strong partner for projects requiring standardized, quality-assured sequencing and biomarker validation.

How they like to work

LGC consistently participates as a specialist contributor rather than leading consortia — all four projects had them in participant or third-party roles. Despite only four projects, they connected with 81 unique partners across 17 countries, indicating they join large, well-funded international consortia where their standardization and measurement expertise fills a specific technical niche. This makes them a reliable, low-friction partner who delivers defined technical contributions without seeking project governance.

With 81 unique consortium partners across 17 countries from just four projects, LGC operates within large pan-European research networks. Their reach spans well beyond the UK, with strong connections across EU member states in health and research infrastructure communities.

What sets them apart

LGC brings something most academic partners cannot: commercial-grade measurement science, ISO standardization expertise, and quality assurance infrastructure applied to genomics and diagnostics. For consortium builders, this means having a partner who can ensure analytical methods are reproducible and meet regulatory standards — critical for projects aiming at clinical translation or assay commercialization. Their position as a large private company with deep roots in reference standards makes them a credibility anchor in health and genomics proposals.

Highlights from their portfolio

• MIRIADE
  Largest EC contribution (EUR 303,173) — addresses dementia diagnosis through multi-omics biomarker discovery with direct clinical validation and commercialization goals.
• EASI-Genomics
  Major European genomics infrastructure project providing open access to advanced sequencing technologies, positioning LGC within the continent's core research infrastructure network.